navigating biosimilars: implications for clinicians (red line)
Published 6 years ago • 10 plays • Length 8:32Download video MP4
Download video MP3
Similar videos
-
0:50
navigating biosimilars: introduction
-
3:39
navigating biosimilars: biologics landscape (orange line)
-
10:00
navigating biosimilars: biologics and biosimilars (gray line)
-
10:58
navigating biosimilars: us regulatory requirements (yellow line)
-
6:31
navigating biosimilars: patient education (green line)
-
3:00
biosimilars: complex copycat drugs
-
1:45
what is a biosimilar? - video explainer
-
42:43
regulatory highlights for biosimilars and interchangeables (9of15) redi – may 29-30, 2019
-
8:03
navigating biosimilars: extrapolation, naming, substitution (blue line)
-
35:31
understanding biosimilars: how the availability of biosimilars will impact clinical practice
-
38:15
biosimilars and biologics
-
17:57
understanding biosimilars: differences between biosimilars and reference products
-
53:18
utilization of biosimilars: achieving value-based plan management
-
8:10
module 6: biosimilars—advances in research and development
-
0:51
fast facts about extrapolation for biosimilars - amgen science
-
6:24
module 4: biosimilars—advances in research and development
-
33:12
biosimilar therapy 101
-
2:41
clinical studies for biosimilars
-
3:48
module 2: biosimilars—advances in research and development
-
0:50
introduction: biosimilars—advances in research and development
-
0:19
biosimilars—advances in research and development
-
1:40
biosimilars 101